ARTICLE | Clinical News
Revolade eltrombopag regulatory update
December 8, 2014 8:00 AM UTC
GlaxoSmithKline submitted an MAA to EMA for Revolade eltrombopag to treat severe aplastic anemia in adults who have had an insufficient response to immunosuppressive therapy. Revolade is approved in t...